Ceramat’s 3D‑Printed Grafts Put India on Global Medical Map with TDB-DST Support

Representative Image

In a significant stride toward strengthening India’s medical technology ecosystem, the Technology Development Board (TDB) under the Department of Science & Technology (DST) has extended financial assistance to Ceramat Private Limited, Palghar, Maharashtra, for the commercialisation of advanced 3D-printed patient-specific bone grafts.

The project, titled “Calcium Phosphate based Standard and Customized Patient Specific Grafts by 3D Printing via Digital Light Processing Technique and Extrusion-based Equipment”, aims to transform the way bone grafts are manufactured and delivered in India. By leveraging indigenously developed bioceramic materials and cutting-edge additive manufacturing technologies, Ceramat seeks to reduce dependence on imported medical products and establish India as a hub for personalised healthcare solutions.

Ceramat’s Vision for Indigenous Innovation

Ceramat makes special powders and ceramics (like hydroxyapatite and calcium phosphate) that are very similar to the minerals in real human bone. These materials are shaped into grafts — pieces doctors use to repair or replace damaged bone.

Instead of making generic grafts, Ceramat uses advanced 3D printers to create patient‑specific grafts that match the exact shape of someone’s bone. This means every graft can be custom‑fit, improving recovery and reducing complications.

Think of it like this: if you break a part of your bone, instead of using a “one‑size‑fits‑all” piece, doctors can now give you a graft that’s tailor‑made for your body.

Ceramat Private Limited was founded with a mission to develop and commercialise

 bio-ceramics and advanced ceramics that serve as high-quality import substitutes. Its portfolio includes biomaterials such as:

• Hydroxyapatite
• Beta-tricalcium phosphate
• Biphasic calcium phosphate
• Bioactive glass

These materials find applications across orthopaedics, oral care, cosmetics, and industrial sectors.

The Technology Behind Patient-Specific Grafts

The initiative integrates Digital Light Processing (DLP)-based 3D printing and extrusion-based 3D printing with indigenous calcium phosphate biomaterials. These complementary approaches will allow Ceramat to manufacture both standard and customised grafts, offering:

• Complex geometries that mimic natural bone structures
• Patient-specific designs for personalised medical care
• Enhanced flexibility in clinical applications

Aligning with Aatmanirbhar Bharat

The project is closely aligned with the government’s vision of Aatmanirbhar Bharat, focusing on advanced manufacturing and indigenous medical technology development. By reducing reliance on imported bioceramic and orthobiological products, the initiative will:

• Strengthen domestic supply chains
• Create opportunities for global market expansion
• Position India as a technology developer rather than just a consumer

Why It’s Globally Relevant

Ceramat’s work matters far beyond India. By producing advanced bone grafts locally, it reduces the country’s dependence on costly imports and makes treatment more affordable. At the same time, mastering patient‑specific 3D printing puts India in direct competition with global medical technology leaders.

This innovation reflects a broader shift in healthcare toward personalized solutions, where treatments are tailored to each individual rather than relying on generic options. Because the same techniques can be applied to dental implants, facial reconstruction, and even cosmetic surgery, Ceramat’s approach has the potential to influence multiple industries worldwide. In essence, India is positioning itself not just as a healthcare consumer, but as a healthcare innovator with solutions that can serve patients across the globe.

Conclusion

The collaboration between TDB-DST and Ceramat Private Limited marks a pivotal moment in India’s healthcare innovation journey. By combining indigenous biomaterials with state-of-the-art 3D printing, the project not only addresses critical medical needs but also reinforces India’s commitment to self-reliance, innovation, and global competitiveness in medical manufacturing.

Material	Application
Hydroxyapatite	Bone grafts, implants
Beta-tricalcium phosphate	Orthopaedics, oral care

4baseCare Launches Targt Indiegene® V2, Bringing A Biology-First Approach to Comprehensive Cancer Profiling

• Five years after the launch of Indiegene V1, the next generation expands to 2,206 genes with most comprehensive coverage of Hallmarks of Cancer, HRD scoring and 36 HRR genes profiling, and 299 fusions, individualised Tumour Mutation Burden (iTMB) score with percentile scoring

4baseCare, a precision oncology company building genomic and clinical intelligence for diverse populations, today announced the launch of TARGT Indiegene® V2, the next generation of its comprehensive genomic profiling (CGP) test for cancer biomarker testing.

The journey began on 15 August 2021, when 4baseCare launched the first Indiegene developed from insights generated through Indian tumour genomics and with the ambition of making comprehensive cancer profiling more accessible. Five years of continuous innovation, clinical experience and genomic insights have now led to Indiegene V2.

With 2,206 genes, V2 significantly expands the genomic breadth of the original panel. More importantly, it introduces a different way of looking at cancer.

Cancer is more than a mutation. Tumours are driven by interconnected biological processes that influence growth, survival, DNA repair, immune evasion and progression. TARGT Indiegene® V2 brings this perspective into CGP through genomic coverage mapped across the Hallmarks of Cancer.

Key capabilities include:

• 2,206 genes for broad genomic profiling
• Hallmarks of Cancer-led coverage to understand the biology driving tumour behaviour
• Immunotherapy biomarkers like MSI and individualised Tumour Mutation Burden (iTMB) score with percentile scoring. 
• HRD scoring and comprehensive coverage of 36 HRR genes. 
• CNVs and 299 clinically relevant fusions, among the most extensive fusion coverage available in commercial CGP assays

“Indiegene V2 is not simply a larger gene panel. It represents a shift from looking for individual biomarkers to understanding the biology behind cancer. As we take Indiegene to more patients and clinicians across global markets, our ambition remains the same, which is to make comprehensive, meaningful precision oncology accessible across diverse populations.” said Hitesh Goswami, Co-founder & CEO, 4baseCare

“Developed through 4baseCare’s experience in population-relevant oncology and now being taken to global markets, TARGT Indiegene® V2 represents the next chapter in our vision to build globally relevant precision-oncology solutions for diverse and historically underrepresented populations”, Kshitij Rishi, Co-Founder and COO, 4baseCare

About 4baseCare

Backed by Infosys and Illumina, 4baseCare is a precision oncology company working to make personalised cancer care more accessible, inclusive and data-driven. The company combines advanced genomic testing, population-relevant clinico-genomic datasets, real-world evidence and AI-powered analytics to support more informed cancer-care decisions. Headquartered in Bengaluru, 4baseCare is expanding its precision oncology footprint across India and international markets with advanced genomics labs in Dubai, Nepal and Philippines. 4baseCare OncoTwin, an AI-based Oncology Digital Twin platform was recently selected for MSKCC iHub program.

Ayati Devices Secures ₹15 Cr Pre‑Series A From Inflexor Ventures to Scale Global Diabetic Foot Diagnostics

Ayati Devices, a Bengaluru-based medical technology and device manufacturing company developing precision diagnostic solutions for diabetic foot complications and peripheral vascular disease, has raised INR 15 Crore in a Pre-Series A funding round led by Inflexor Ventures. This marks the company's first institutional investment and will accelerate the commercialization of its next-generation diagnostic technologies, expand its domestic and international presence, strengthen manufacturing capabilities, and deepen investments in research, regulatory approvals, artificial intelligence, and global talent. Ayati Devices has been incubated at IITB-SINE as part of the institute’s translational research program.

India's medical devices sector is accelerating on innovation and government incentives, even as diabetes becomes one of the world's biggest health challenges. Over 90 million Indians live with diabetes. Many lose foot sensation silently until complications strike, and over 50,000 lower-limb amputations occur in India each year, most preventable through timely diagnosis.

Founded by Nishant Kathpal, Ayati Devices builds clinically accurate, portable, and affordable diagnostic technologies that bring preventive care beyond tertiary hospitals into primary care centres and diabetes clinics. Ayati's portfolio covers the full diabetic foot diagnostic pathway. Vibrasense delivers clinician-independent neuropathy screening in under five minutes; Vibrasense+T adds large- and small-fibre nerve assessment. Vasosense detects Peripheral Artery Disease in two minutes without a specialist, while Angiocam turns real-time tissue perfusion imaging, once prohibitively expensive, into an accessible, portable tool. Completing the suite, the PODIA Trolley offers a pay-per-test screening station with zero upfront capital investment.

Ayati's technologies already hold regulatory clearances across major global markets, including CDSCO (India), the U.S. FDA, CE Mark (Europe), and approvals in Sri Lanka, Malaysia, and the UAE. The company has deployed over 10,000 devices across 30+ countries, backed by a growing international distributor network and clinical deployments at leading institutions such as Medicover Hospital and Aster Hospital.

The addressable market spans USD 15 billion globally and USD 1.4 billion in India alone, across diabetic neuropathy, peripheral vascular disease, and tissue perfusion imaging. Ayati's technology also extends into plastic surgery, wound care, burn management, cardiovascular diagnostics, and reconstructive medicine, widening its long-term potential.

The capital will fund Angiocam's commercialisation, expand go-to-market operations at home and abroad, strengthen manufacturing and supply chain capacity, accelerate R&D in AI-enabled diagnostics, secure further regulatory approvals, grow the IP portfolio, and build out engineering, clinical, regulatory, and global business development teams.

Looking ahead, Ayati will deepen its presence across Europe, the U.S., the Middle East, Southeast Asia, Australia, and Latin America through its distribution network, while evaluating direct commercial operations in key markets as demand scales. It will also expand its pay-per-test screening model across hospitals, primary care clinics, and community programmes, making preventive diagnostics far more accessible.

Commenting on the funding, Nishant Kathpal, Founder & CEO, Ayati Devices, said, "Diabetic foot remains one of the most overlooked healthcare challenges, despite being largely preventable with timely screening. At Ayati, we have focused on building technologies that make advanced diagnostics objective, affordable, and accessible beyond tertiary hospitals - right from primary care clinics to community screening programs. This investment marks an important milestone in our journey. It will accelerate our product roadmap, strengthen our global presence, and help us reach millions of patients before complications become irreversible. We are grateful to all our investors for believing in our vision of transforming diabetic foot care worldwide."

Explaining the investment rationale, Pratip Mazumdar, Partner, Inflexor Ventures, said,"India's medical devices sector, driven by innovation and government incentives, is rapidly expanding along with a strong structural tail-wing targeted towards localized technology and manufacturing. Ayati is a platform play in the medical devices sector and exactly the kind of company Inflexor exists to back: a founder with deep technical conviction, a product built from genuine clinical insight, and a platform that is already demonstrating adoption across both domestic and international markets. The scale of the opportunity is as large as the unmet need. Ayati's multi-product platform, proprietary hardware-software integration, and growing IP portfolio give it the moat to become the global standard of care in non-invasive vascular and neurological diagnostics."

The funding represents a significant milestone for Ayati Devices as it transitions from technology validation to accelerated commercial scale. With regulatory-ready products, global market access, and clinical adoption across multiple geographies, the company is set to make advanced diagnostics more affordable and accessible worldwide. As diabetes rises globally, Ayati aims to shift care from reactive treatment to early intervention, preventing amputations and improving outcomes for millions worldwide.

TDB Backs Griva Health to Boost India’s Indigenous Medtech Manufacturing in Cervical Cancer Screening

The Technology Development Board (TDB) under India’s Department of Science & Technology (DST) has partnered with Visakhapatnam-based Griva Healthcare Pvt. Ltd. to commercialize GrivaVision, an AI-powered portable colposcope designed for early detection of cervical pre-cancerous lesions.

Founded in 2025, by Nidun Jacob and Parvathi Radhakrishnan, Griva Healthcare will establish manufacturing in Kollam, Kerala, strengthening India’s domestic medtech ecosystem.

Company Overview: Griva Healthcare Pvt. Ltd.

• Founded: January 2025
• Founders/Directors: Nidun Jacob, Parvathi Radhakrishnan
• Headquarters: Visakhapatnam, Andhra Pradesh, India
• R&D Base: AIC-AMTZ Medivalley, Visakhapatnam
• Upcoming Manufacturing Hub: Kollam, Kerala
• Capital Structure: Authorized capital ₹1 lakh; paid-up capital ₹1 lakh
• Status: Active, unlisted private limited company

Technology: GrivaVision

• Device Type: Portable digital colposcope with AI-assisted capabilities
• Classification: Class B non-invasive medical device; CDSCO Class B manufacturing licence
• Standards: ISO 13485 compliant; WHO-approved Automated Visual Evaluation (AVE) standards; ABDM-compliant software
• Features: High-definition camera, in-built display, user-friendly interface, advanced optics, proprietary AI-enabled diagnostic software
• Patent: Hardware architecture patented in India by Griva Healthcare
• Localization: Over 50% of components sourced indigenously

The device is designated as a Class B non-invasive medical instrument and holds a CDSCO Class B manufacturing licence. It is being developed under ISO 13485 quality standards, ensuring compliance with international benchmarks for medical devices.

Griva Healthcare has secured a patent in India for its proprietary hardware architecture, reinforcing its innovation credentials. Currently, the company is conducting R&D at AIC-AMTZ Medivalley in Visakhapatnam, with support from TDB enabling the transition to commercial-scale manufacturing at its upcoming facility in Kollam, Kerala.

A defining aspect of the initiative is its emphasis on indigenous development and localization. More than 50% of the components are sourced domestically, underscoring India’s growing medtech capabilities. Scaling commercialization is expected to strengthen the national medical device value chain and deliver a cost-effective Indian alternative for cervical cancer diagnostics, reducing reliance on imported technologies.

Image – YouTube/GrivaHealth

Strategic Significance

• Healthcare Impact: Enables early detection of cervical pre-cancerous lesions
• Accessibility: Designed for primary and community healthcare settings
• Policy Alignment: Supports India’s self-reliance in medical technologies
• Digital Integration: ABDM-compliant software ensures compatibility with India’s digital health ecosystem
• Economic Impact: Strengthens domestic medical device value chain

Leadership & Government Statements

• Rajesh Kumar Pathak, Secretary, TDB: “Early detection can make a decisive difference in addressing cervical cancer. Indigenous technologies such as GrivaVision demonstrate how medical devices, digital health and artificial intelligence can come together to address a critical healthcare need at scale.”
• Griva Healthcare Leadership: Expressed gratitude for TDB’s support, noting that the assistance will enable transition from R&D to commercial-scale manufacturing and expand access to AI-assisted cervical cancer screening.

Quick Reference Table

Aspect	Details
Founders	Nidun Jacob, Parvathi Radhakrishnan
HQ	Visakhapatnam, Andhra Pradesh
Manufacturing	Kollam, Kerala
Device	AI-powered portable colposcope
Standards	ISO 13485, WHO AVE, ABDM-compliant
Classification	CDSCO Class B
Patent	Proprietary hardware architecture
Localization	>50% components sourced indigenously

MedTech Startup Bioscan Research Raises $1 Mn in Seed Round Led by Unicorn India Ventures

• Bioscan Research is an innovation-driven medical device company pioneering non-invasive diagnostic solutions for early disease detection.
• Funds raised will be strategically deployed for market expansion, additional regulatory approvals, product upgradation and new IP creation. 
• In the last 12 months the company has witnessed 5x growth. 
• The company’s goal is to grow 3x in the next 12 months and plans to expand in India and overseas market. 
• Bioscan Research aims to improve traumatic brain injury patient outcomes via an objective assessment for early detection at a pre-symptomatic phase with the help of machine learning powered NIRS device - CEREBO.

MedTech startup Bioscan Research which is leveraging deeptech in optics, electronics, mechanics and software to develop, test, manufacture and commercialize affordable medical devices for early detection of brain injuries non-invasively, has raised $1 million in a seed round led by Unicorn India Ventures. The funds raised will be strategically deployed for market expansion, additional regulatory approvals, product upgradation and new IP creation.

Incorporated in 2017, by Anupam Lavania and Shilpa Malik, Bioscan Research aims to improve traumatic brain injury patient outcomes via an objective assessment for early detection at a pre-symptomatic phase with the help of machine learning powered NIRS device - CEREBO. The flagship product CEREBO, is an advanced intra-cranial injury detector designed to assist in managing trauma patients, even in the absence of visible symptoms, ensuring timely intervention within the golden period.

Commenting on the fund raise, Co-founders, Bioscan Research says, “We harness light to reveal what the eyes can’t see — giving doctors clarity, patients hope, and technology a heart. More than 50 million suffer from traumatic brain injury each year and 50-90% of patients with mild traumatic brain injury go unidentified. With this current round, we will be able to upgrade our product and bridge the limitations of traditional tools and provide urgent care in India and internationally.”

In the last 12 months the company has witnessed 5x growth and is redefining how critical conditions are identified—enabling faster clinical decisions, improved outcomes, and more accessible care worldwide

Anil Joshi, Managing Partner, Unicorn India Ventures says, “We have been investing in highly innovative medtech companies quite consistently as we believe the healthcare industry still has a big gap to address in countries like India. We believe the market is huge and the research is evident on how people are suffering from head injuries and brain trauma every year. It is time to bring the correct technology that will diagnose early symptoms and understand what the patient is suffering from. Bioscan Research is making it possible to detect intra-cranial haemorrhage non-invasively. The company has witnessed progress in the last 12 months and has upgraded its technology solutions. Hence, we believe the market opportunity is huge and the company has built the right momentum to capitalise on this segment.”

Over the next 12 months the company’s goal is to grow 3x and plans to expand in India and overseas markets.

About Bioscan Research

Bioscan Research is an innovation-driven, ISO 13485:2016–certified medical device company pioneering non-invasive diagnostic solutions for early disease detection. By integrating photonics, precision engineering, and machine learning–driven analytics, Bioscan Research is redefining how critical conditions are identified—enabling faster clinical decisions, improved outcomes, and more accessible care worldwide. Its flagship product, Cerebo, is an advanced intracranial injury detector designed to assist in managing trauma patients, even in the absence of visible symptoms, ensuring timely intervention within the golden period.

About Unicorn India Ventures

Started in 2016 by Bhaskar Majumdar and Anil Joshi, Unicorn India Ventures is a deep tech focused early-stage fund that invests in emerging and visionary startups. Unicorn India Ventures launched its first fund with a corpus of Rs 100 crore and invested in 17 companies like SmartCoin, Open Bank, Sequretek, Pharmarack, Genrobotics, Clootrack, FutureCure to mention some. The Fund has emerged as the best performing early-stage fund in India with the stellar exits provided by the fund to its LPs. Fund II is a Rs 300 Cr fund launched in 2020 that has invested in 20 companies so far like Gamerji, Probus, Daalchini, Windo, Finsall. Most of the portfolio is scaling up fast and has had several uprounds.

Unicorn India Ventures has closed its Rs 1200 Cr Fund III surpassing the target of Rs 1000 Crore. With this Fund, UIV aims to build a portfolio of 20 startups that are focused mostly in the deep tech sector that includes semiconductor, space tech, and medical diagnostics apart from AI infrastructure and India digital platforms. Companies like Netrasemi, Kluisz, OrbitAID, TakeMe2Space, Aurassure, EyeROV, QubeHealth to name a few.

Recently, IIT-Madras and Unicorn India Ventures launched Rs 1000 crore “IITM Unicorn Frontier Fund I”. UIV is a fund with engineering DNA and has been backing deeptech companies for over a decade. The Fund has investors across the globe represented by institutions, family offices and UHNIs. The Fund has a global viewpoint while sourcing companies throughout the country.

Gates Foundation Backs Bengaluru's Remidio’s AI Retinal Platform to Tackle Maternal Health Risks in Africa & India

Remidio Innovative Solutions has received a grant from the Gates Foundation to advance its Oculomics platform, which uses retinal imaging and AI to detect signs of systemic disease, for maternal health applications in low- and middle-income countries (LMICs). The initiative will focus on improving early risk assessment for major pregnancy complications, including pre-eclampsia (PE), anemia and gestational diabetes mellitus (GDM). The program will be carried out across countries in Africa and India, regions that together bear the overwhelming share of the global maternal and perinatal disease burden


The scale of the problem is stark. There are approximately 2 million stillbirths worldwide each year, equivalent to one every 16 seconds, and 84% of these occur in LMICs. Hypertensive disorders of pregnancy, particularly pre-eclampsia, are among the leading placental causes of these deaths. The same conditions are also among the leading causes of maternal mortality globally, contributing to an estimated 42,000 maternal deaths annually. Gestational diabetes mellitus affects approximately one in six pregnancies worldwide, with a disproportionately high burden falling on these same populations. Together, these conditions are major contributors to stillbirth, preterm birth, and long-term cardiovascular and metabolic complications that affect both mothers and their children.

The women most at risk from pre-eclampsia and gestational diabetes are often the least likely to reach a laboratory or a specialist in time," said Dr. Anand Sivaraman, Chief Executive Officer and Founding Director, Remidio. "A retinal image takes seconds and can be captured by a frontline worker with minimal training. This grant allows us to ask a clear question with real rigour: can the platform already deployed widely for diabetic retinopathy also help identify pregnancies at risk, in the places where that information is needed most.

The biological link between retinal microvascular changes and systemic vascular and metabolic disease is now well established. Yet in the primary care and community settings where maternal mortality is concentrated, the diagnostic tools that currently support early risk stratification, namely complex laboratory assays, biochemical biomarkers and Doppler-based assessments, are largely unavailable at the point of care, requiring laboratory infrastructure, trained personnel and referral pathways that simply do not exist for most pregnant women in LMICs. Non-invasive retinal imaging, by contrast, is quick, easy to perform by frontline health workers with minimal training, and inherently scalable, making it uniquely suited to bringing advanced risk assessment to the front lines of antenatal care.

The retina is the only place in the body where blood vessels can be observed directly and without an invasive procedure, said Dr. Divya Rao, Chief Medical Officer and Head of AI, Remidio. The microvascular and metabolic changes associated with pre-eclampsia and gestational diabetes leave detectable signatures. Having built and validated our retinal AI on a very large and diverse image dataset, our task now is to prove these signals hold up in community antenatal care, in the hands of frontline workers, across different populations. Evidence, not assumption, will decide where this proves useful.

Remidio's portable, smartphone-based retinal imaging platform is already widely deployed across primary care and community screening programs for diabetic retinopathy, glaucoma and AMD. The grant will extend this platform into maternal health, with implementation across partner sites in Africa and India.

About Remidio -

Today, the human eye is unlocking early insights into systemic health, and Remidio is at the forefront of this transformation. Remidio is a pioneer in AI-driven eye care, leading the shift from care of the eye to healthcare through the eye. As the first company to receive CDSCO approval in India for our adaptive ophthalmic AI, in addition to CE marking in Europe under Class II EU-MDR, we are redefining how diseases like diabetic retinopathy, glaucoma, and AMD are detected early, in close to patient contexts, while remaining confident of extending this to systemic disease detection such as CVD, CKD and liver diseases, in the future.

With CE-marked, FDA 510(k)-registered devices, our solutions have screened 16 million+ patients across 55 countries, integrating teleophthalmology and AI for fast, accurate diagnoses. Our innovative retinal imaging solutions ensure precision and efficiency in clinical workflows. Our journey began humbly - thanks to the chance meeting of our founder, with a mission driven ophthalmologist, who brought into focus the need for decentralizing eye testing with simple to use and affordable devices. That conversation, 15 years back, sparked a vision to make high-quality preventive care accessible to all. Guided by innovation, empathy, and a commitment to global impact, our journey is just beginning!

Tata Elxsi and OpenAna Unveil Anatel™, An AI‑Native Platform Redefining Regulatory‑Ready MedTech Software Engineering

Tata Elxsi and OpenAna have jointly launched AnaTel™, an AI‑native software engineering platform for healthcare and MedTech, designed to streamline regulatory compliance and accelerate SaMD development cycles by up to 60%. The debut at DeviceTalks Boston 2026 marks a significant milestone in AI‑driven, regulatory‑ready software delivery for medical technology.

AnaTel™ embeds autonomous AI agents directly into the engineering workflow. Unlike developer productivity tools that focus on code generation alone, AnaTel™ operates across the full AI-Driven Software Delivery Lifecycle, from requirements and architecture through deployment, verification and validation, and continuous optimization, making it a true end-to-end engineering execution platform for regulated environments.

AnaTel™ functions as a configurable AI software team, producing code, documentation, test cases, and compliance artifacts through a specialized Healthcare and Life Sciences agent tailored for MedTech regulatory and engineering demands.

Human engineers and regulatory specialists maintain oversight at every critical review and decision stage. AnaTel™ integrates eSTAR‑aligned submission preparation, requirements traceability matrices, verification and validation records, and audit‑trail documentation directly into daily engineering workflows. By embedding compliance into execution, the platform shortens SaMD (Software as a Medical Device) development and change assessment cycles from eight weeks to just 72 hours, delivering productivity gains of up to 60%.

Key Highlights of AnaTel™

• Launch Context: Introduced at DeviceTalks Boston 2026 by Tata Elxsi and OpenAna
• Purpose: End‑to‑end AI‑native platform for regulated healthcare and MedTech software engineering
• Impact: Cuts SaMD timelines from 8 weeks to 72 hours, with up to 60% productivity gains

Regulatory Drivers

• FDA Draft Guidance (2025): AI‑Enabled Device Software Functions now require lifecycle documentation, traceability, and validation evidence
• Europe’s MDCG 2025‑26: Similar emphasis on rigorous documentation and compliance
• Challenge: Manual assembly of requirements, test cases, and regulatory artifacts across disconnected tools. AnaTel™ embeds compliance into daily workflows, eliminating bottlenecks

Platform Capabilities

• Autonomous AI Agents: Configurable AI software teams generate code, documentation, test cases, and regulatory artifacts
• Healthcare Expert Agent: Fine‑tuned for MedTech regulatory contexts, ensuring contextualized compliance
• Workflow Coverage: Requirements → Architecture → Deployment → Verification/Validation → Continuous Optimization
• Submission Support: eSTAR‑aligned preparation, traceability matrices, audit‑trail documentation

Tata Elxsi’s Role

• Expertise: Decades of experience in regulated medical device environments
• Strengths: Design‑led, AI‑first engineering, ISO 13485 certified Healthcare & Life Sciences practice
• Contribution: Shaped AnaTel™’s reasoning around traceability, validation, and compliance

OpenAna’s Role

• Platform Innovation: Provides Ana, a multi‑agent autonomous engineering system spanning software, security, DevOps, and AI/ML
• Differentiator: Goes beyond coding assistants — full ownership of engineering workflows, with enterprise‑grade guardrails and auditable AI
• Contribution: Embedded autonomous engineering into MedTech’s demanding regulatory domain

Leadership Perspectives

• Sreevatsa Sahasranaman (Tata Elxsi): AnaTel™ accelerates regulatory‑ready engineering while keeping human experts in control
• Rajiv Sondhi (OpenAna): Autonomous AI agents act as reliable co‑engineers in regulated healthcare
• Muthusamy Selvaraj (Tata Elxsi): AnaTel™ exemplifies STEP.UP co‑innovation — accountability for outcomes, not just technology

Strategic Significance

• For Healthcare Teams: Reduces compliance burden, integrates documentation into workflows
• For Regulators: Provides transparent, auditable AI‑driven engineering evidence
• For Industry: Sets a benchmark for AI‑native platforms in regulated environments, bridging speed with safety. 

Hinduja Scholarships Fuel MedTech Innovation at King's College London

Hinduja Foundation, the philanthropic arm of the Hinduja Group, has announced scholarships 2026 for Indian origin students to pursue the MSc in MedTech Innovation & Entrepreneurship at King’s College London. In 2024, the Hinduja Foundation UK made a significant philanthropic donation to world renowned King’s College London to establish the Hinduja King’s Health Partners’ Academy. This groundbreaking partnership includes support for full four-year PhD studentships in healthcare technologies at the School of Biomedical Engineering and Imaging Sciences and one year MSc. MedTech Innovation and Entrepreneurship will benefit healthcare communities in both the UK and India. Furthermore, the partnership has brought nurses’ training, observer ships and online leadership training courses provided by Guy’s and St Thomas’ Hospitals NHS Foundation Trust to the P.D. Hinduja Hospital, Mumbai.

Three PhD and two MSc Hinduja scholars started their studies at Kings College London in October 2025 and one PhD scholar joined in February 2026.

Applications are still welcome for four PhDs and five MSc scholarships for the coming 2026- 2027 academic year starting in October. Further details on the Hinduja Foundation UK PhD scholarships and instructions on how to apply can be found here Hinduja Scholars - Surgery CDT. Applications are open until 30 May 2026.

Meanwhile five MSc MedTech Innovation and Entrepreneurship scholarships are available – one at 80% and four at 50% for Indian citizens. Further details are given on this link Hinduja Scholarship for MedTech Innovation C Entrepreneurship MSc | King's College London and applications close on 19 June 2026.

The scholarships will empower Indian students with access to global expertise, real-world healthcare environments, and innovation-led learning, enabling them to address critical clinical needs and contribute to the future of healthcare in India and globally at King’s College London, recognised for its excellence in education and research. It is committed to driving positive and sustainable change through impactful research, outstanding education, and service to society, both in the UK and globally.

Ashok Hinduja, Chairman of Hinduja Foundation said, “Guided by our philosophy of ‘Act Local, Think Global’, we believe investing in future-ready talent is essential to building resilient healthcare systems in India that are aligned with global standards, contributing to the vision of a Viksit Bharat. Through this partnership, we aim to enable Indian students to access global expertise. The focus is on strengthening India’s capabilities in healthcare and expanding the scope of knowledge and research linked to India. Over the long term, the objective is to advance India’s role in the global healthcare landscape.”

About Hinduja Foundation:

Deeply rooted on the philanthropic principles of the Founder of Hinduja Group, Shri Parmanand Deepchand Hinduja, this Foundation is a public charitable trust established first in Mumbai in 1968. In its 50 years of existence, with the guidance of the Hinduja Family and support from Hinduja Group companies, its global presence has led to the development in the fields of Education, Healthcare, Water Stewardship, Sustainable Rural Development, Social Welfare, Arts & Culture and Sports. It also works actively with the Group Companies in delivering an aligned approach to creating Social Impact.

About Hinduja Group:

The Hinduja Group is a 111-year-old transnational conglomerate with over 250,000 employees across 100 countries. Founded in 1914 by Late Shri Parmanand Deepchand Hinduja, the Group has evolved into one of India’s most respected diversified business houses, with a leadership in automotive and mobility, banking and financial services, IT and digital solutions, energy and healthcare. Through its enterprises, the Group has contributed to India’s industrial evolution and economic progress while building strong global partnerships and market presence worldwide. Anchored in robust governance, disciplined risk management and long-term value creation, the Hinduja Group is guided by its enduring credo, “My Dharma is to work so that I can give,” reflecting a legacy that combines global enterprise with nation-building and community commitment.

About King’s College London

King’s College London is amongst the top 35 universities in the world and 5th best in the UK (QS World University Rankings 2026), and one of England’s oldest and most prestigious universities.  With an outstanding reputation for world-class teaching and cutting-edge research, King’s maintained its sixth position for ‘research power’ in the UK (2021 Research Excellence Framework). King's has more than 42,000 students (including more than 12,800 postgraduates) from some 190 countries worldwide, and 8,500 staff.

Ex-Google, Amazon Execs-Founded SwishX Launches World’s Ist Agentic AI Platform for Pharma & Medtech

• Bengaluru-based startup seed-funded for $2.2 million backed by Powerhouse Ventures, Blume Ventures, Sadev Ventures, Atrium Ventures, and others
• Targets $5M ARR and 100+ enterprise clients
• Plans expansion across emerging markets including Latin America, Southeast Asia, Middle East, Africa, and Eastern Europe

SwishX today announced its launch, introducing the World’s first Agentic AI platform built exclusively for pharmaceutical and medtech companies, aimed at transforming sales, marketing, distribution, and business growth through artificial intelligence.

The Bengaluru-headquartered startup is targeting $5 million in contracted ARR and 100+ Enterprise clients by end of current FY 2026-27, and plans expansion into Latin America, Southeast Asia, the Middle East, Africa, and Eastern Europe. SwishX has also raised $2.2 million in seed funding backed by Powerhouse Ventures, Blume Ventures, Sadev Ventures, Atrium Ventures, and other investors. These emerging markets, along with India, represent a $400 billion pharma and medtech opportunity, with commercial operations expected to grow to $770 billion by 2033 at a CAGR exceeding 12%.

India, dubbed as the ‘pharmacy of the world’, alone supplies 20% of the world’s medicines, and exports to over 200 countries, and is home to the highest number of US FDA-approved manufacturing plants outside the United States. However, most companies still lack real-time visibility into key business questions - which public tenders out of thousands they have a real shot at winning, where is the revenue leakage happening, what is actually selling at the retailer level, whether marketing efforts to engage doctors are generating results? All this is part of a long-standing problem in the pharma industry, where many critical commercial decisions still depend on spreadsheets, disconnected software, manual workflows, and delayed reporting. SwishX aims to address these gaps through AI Agent-led solutions and improve revenue outcomes by up to 30%.

SwishX’s specialized AI Agents capture siloed data, automate business workflows, learn nuances of every decision and build a functional memory to help business teams accelerate their execution.

While starting with India, SwishX is helping the pharma companies to further grow in other countries as well by combining AI with local market data of different countries. The platform autonomously evaluates thousands of tenders globally, surfaces most high-probability win opportunities, analyzes complex 500+ pages documents, recommends likely winning pricing, and drafts proposals within minutes. It also enables quick conversion of long marketing PDFs into highly engaging personalized video reels for doctors - reducing the time taken from weeks to just one day.

Dushyant Sapre, Founder & CEO, SwishX, said, “India’s pharma sector, recognized as the Pharmacy of the World, drives revenues of over USD 65 billion and Emerging Markets combined drive USD 400 billion while distributing into over 200 countries. Manufacturing and R&D have become genuinely world-class, but how these companies sell, market, and distribute, is still stuck in the past. Companies often struggle to know where losses are happening, what is selling, which tenders matter most, or how effectively teams are executing in the market. AI Agents change that completely. The next big transformation in this industry is not going to happen in the lab. It is going to happen in how these companies go to market. For the first time, companies can move to real-time autonomous execution.”

SwishX is purpose built specifically for the complexity of emerging markets. India alone has over 1.2 million pharmacies, compared to just ~1,00,000 in the US. Additionally, 30-60% of procurement happens through government tenders, rate contracts and generic competition is significantly more intense.

SwishX is being launched at a time when pharma companies are accelerating AI adoption with industry estimates suggesting that AI could unlock $60–110 billion in annual value globally in this sector.

SwishX is not a traditional CRM or reporting tool, but a complete Agentic AI-platform combining intelligence and execution. Over the long term, SwishX aims to build a vertically integrated AI system for the entire value chain of life sciences companies - faster generic and biosimilar drug discovery, drug development, and autonomous multi-market commercial execution. For now, SwishX is anchored where the pain is most immediate and most measurable.

About SwishX

SwishX is a Bengaluru-based Agentic AI startup building “outcome first” solutions for pharmaceutical, medtech, and life sciences companies across Emerging Markets. It is the world's first agentic AI platform designed as a system of action for the pharma industry, that not only turns complex data into clear decisions, but also helps teams execute those decisions faster and at scale using autonomous AI agents.

Built for the complexity of emerging markets, SwishX helps pharma companies move beyond spreadsheets and fragmented systems. It enables companies to improve sales execution, strengthen marketing and channel engagement, streamline distribution networks, and automate critical workflows through autonomous AI agents, proprietary data sets and real-time market intelligence.

The platform spans 4 products: Tender IQ (Agentic AI Tender & RFP Automation), Contract IQ (Agentic AI Hospital Rate Contract Automation), Marketing IQ (Agentic AI HCP & Rep Engagement), Channel IQ (Agentic AI Channel Engagement). The company is SOC-2 compliant with data encryption in transit and rest.

Starting with India, the company plans to expand across Latin America, Southeast Asia, the Middle East, and Africa, with a long-term vision to build a vertically integrated AI platform for the life sciences sector across the full business lifecycle: from generic drug development to multi market distribution.

World’s First Fully Automated Medicine Lab: All Robots No Humans

Japan has unveiled a world-first fully automated medicine laboratory, operating entirely without human researchers. Located at the Institute of Science Tokyo’s Yushima campus, this facility is staffed exclusively by humanoid robots and autonomous machines, marking a radical shift in medical research.

The facility developed by the Institute of Science Tokyo operates with 10 robots, including the humanoid Maholo LabDroid, and no on-site human staff.

Key Highlights

• Location: Yushima campus, Institute of Science Tokyo
• Robots in operation: 10 autonomous machines, including Maholo LabDroid with dual robotic arms
• Functions: Automated cell culture, reagent transfer, temperature-controlled experiments, and repetitive lab tasks
• Expansion goal: 2,000 robots by 2040, aiming to automate the entire medical research pipeline
• No human staff: Operates 24/7 without on-site researchers

Inside the Robot-Run Lab

• Maholo LabDroid: A humanoid robot capable of performing delicate tasks such as stem cell culture and drug testing.
• Other autonomous systems: Handle repetitive lab work with precision, ensuring consistency across experiments.
• Current scale: 10 robots are already in operation.
• Future vision: Expansion to 2,000 robots by 2040, creating a fully autonomous medical research ecosystem.

Maholo LabDroid was among the earliest humanoid robots specifically built for biomedical research. It was first unveiled in 2017 by Japan’s Robotic Biology Institute (RBI), marking the debut of a humanoid laboratory robot designed to automate complex

biological experiments.  

Why It Matters

• 24/7 operation: Robots can run experiments continuously, accelerating discovery.
• Error reduction: Automation minimizes human mistakes in sensitive procedures.
• Drug development speed: Timelines for testing and discovery are compressed significantly.
• AI integration: Plans include combining robotics with AI for hypothesis generation and experimental validation.

Human vs. Robot Labs

Feature	Human-Staffed Labs	Fully Automated Robot Lab
Staffing	Scientists, technicians	10 robots (scaling to 2,000)
Operation Hours	Limited (8–12 hrs/day)	24/7 continuous
Error Risk	Human error possible	Minimized via automation
Scalability	Workforce-dependent	Expandable via robotics
Research Speed	Weeks/months	Compressed timelines

Challenges Ahead

• Ethical oversight: With no humans on site, accountability for results becomes complex.
• Technical reliability: Robots must adapt to unexpected experimental variables.
• Cost barrier: High investment may limit adoption outside elite institutions.
• Human role shift: Researchers may transition into supervisory, AI-integration, and oversight positions.

This lab represents a paradigm shift in medical research, where robots not only assist but fully replace human presence. If successful, it could redefine the future of drug discovery and biomedical innovation worldwide.

Medtronic Launches Adaptive DBS in India: Real‑Time Therapy for Parkinson’s Patients

Medtronic, a global leader in healthcare technology, today announced the launch of its Adaptive Deep Brain Stimulation (aDBS) system, an innovation over conventional DBS, in India to further improve quality of life of patients living with Parkinson’s disease.

The prevalence of Parkinson's disease (PD) in India is roughly 10% of the global burden, which is a considerable public health concern. 

Parkinson’s is a progressive neurological condition that can affect how a person moves and functions in everyday life. Over time, it may make routine activities such as walking, writing, or holding everyday objects more difficult. While movement-related challenges are often the most visible, the condition can also influence other aspects of daily living, including communication, sleep, and overall well‑being. Today, a range of treatment approaches help manage symptoms as the disease evolves. Care is typically tailored over time, with treatment pathways adjusted based on individual needs and clinical assessment by specialists.

Treatment options like Deep Brain Stimulation exist which involve manual adjustment of stimulation levels throughout the day, usually managed by patients or caregivers. Medtronic’s aDBS technology is designed to adapt real time to changes in a patient’s condition or medication needs—helping deliver more consistent symptom management. The aDBS system uses BrainSense™ technology, which has been approved by the U.S. Food and Drug Administration (FDA).

Adaptive deep brain stimulation (aDBS) is designed to automatically adjust therapy based on changes in brain signals or patient activity. By responding in real time, it aims to provide more consistent symptom control, minimize side effects, and help extend the life of the implanted device’s battery.

With India expected to witness a significant rise in Parkinson’s disease cases—projected to become the second-highest globally within the next five years7—the introduction of the aDBS system comes at a critical time. Although there is currently no cure for conditions such as Parkinson’s disease, deep brain stimulation (DBS) has been transforming the lives of patients with Parkinson’s and other neurological disorders for more than three decades. 

DBS uses a small, pacemaker-like device, placed under the skin of the chest, to send electronic signals to an area in the brain that controls movement. To give you relief, these signals block some of the brain messages that cause the movement symptoms of Parkinson’s.

On the occasion, Prateek Tiwari, Senior Director, Neuroscience & Specialty therapies, Medtronic India said, “We are extremely proud to introduce this advanced technology in India, where Parkinson’s disease is an increasingly significant healthcare concern. Our mission has always been to alleviate pain, restore health, and extend life, and the introduction of this system reflects our continued commitment to that mission. This milestone not only reaffirms our dedication to addressing the growing burden of Parkinson’s disease but also strengthens our leadership in bringing cutting-edge healthcare technologies to India to ultimately improve patients’ quality of life.’’

As the burden of a disease such as Parkinson’s will rise, continued investment in cutting-edge technologies will be essential to expanding access to better care, supporting clinicians with deeper insights, and ultimately improving the quality of life for patients across the country.

Patients considering deep brain stimulation (DBS) typically begin by consulting a Movement Disorder Specialist, usually a neurologist, who evaluates whether their condition may benefit from this therapy. DBS follows a coordinated, team-based approach, with patients often referred to a comprehensive DBS clinic or neurosurgery board for further assessment. If considered suitable, a Functional Neurosurgeon—specially trained to perform the procedure—works alongside the care team to implant and program the device.

All information contained herein is for general awareness purposes only, and nothing contained herein should be construed as medical advice or recommendation. Patients should consult their physician to discuss their conditions and seek relevant medical advice.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

From Lungs to Hearts: How Digital Twins Are Revolutionizing Indian Healthcare

Digital twin technology—virtual replicas of organs or entire patient systems—is rapidly emerging as a game‑changer in India’s healthcare ecosystem. By integrating AI, imaging, and real‑time patient data, digital twins enable predictive diagnostics, personalized treatment, and advanced surgical planning.

What is a Digital Twin in Healthcare?

• A digital twin is a virtual model of a patient’s body or organ, created using CT scans, vitals, lab reports, and wearable data.
• Doctors can simulate disease progression, predict treatment responses, and plan interventions with greater accuracy.
• It combines AI, IoT, big data, and imaging workflows for real‑time monitoring and diagnostics.

Key Digital Twin Breakthroughs in India

Respiratory Diagnostics – LTTS AI Lung Digital Twin

• Launch: March 2026, San Jose (by L&T Technology Services).
• Powered by: NVIDIA AI infrastructure.
• Applications: Lung cancer, COPD, infectious diseases.
• Features: Immersive 3D visualization, CT imaging workflows, AI‑driven surgical navigation.
• Significance: First India‑origin MedTech platform with global deployment.

Cardiac Care – Apollo Hospitals

• Use Case: Digital twin simulations of the human heart.
• Purpose: Optimize surgical planning, stent placement, and arrhythmia monitoring.
• Impact: Enables safer, more precise interventions in cardiovascular care.

Oncology – Predible Health & Telerad Tech

• Focus: Tumor modeling and radiotherapy planning.
• Technology: AI‑driven imaging combined with digital twin simulations.
• Benefit: Personalized cancer treatment pathways and reduced radiation risks.

Orthopedics & Prosthetics – IISc Bengaluru

• Research Area: Biomechanical digital twins for orthopedic implants and rehabilitation.
• Goal: Simulate patient‑specific bone and joint mechanics.
• Outcome: Improves implant design and recovery planning.

Personalized Medicine – Datta Meghe Institute (Wardha)

• Project: AI‑driven digital twins for predictive medicine.
• Approach: Integrates patient vitals, imaging, and lifestyle data.
• Potential: Tailored therapies and preventive care models.

Why These Are Breakthroughs

Domain	Breakthrough Example	Impact
Respiratory Care	LTTS AI Lung Digital Twin	Global MedTech leadership, advanced diagnostics
Cardiology	Apollo Hospitals	Precision surgical planning
Oncology	Predible Health, Telerad Tech	Personalized radiotherapy
Orthopedics	IISc Bengaluru	Patient‑specific implant design
Personalized Care	Datta Meghe Institute	Predictive medicine pathways

Challenges Ahead

• Clinical Validation: Large‑scale trials needed for accuracy.
• Data Privacy: Compliance with HIPAA/GDPR critical.
• Infrastructure Gaps: Many hospitals lack AI‑ready imaging systems.
• Regulatory Approvals: FDA/CE certifications required for global adoption.

India’s digital twin breakthroughs are shaping a new era of precision healthcare, with respiratory, cardiac, oncology, and orthopedic applications already underway. These innovations position India as a rising MedTech hub, but scaling will depend on policy support, infrastructure investment, and clinician training.

Benefits for Diagnostics

• Personalization: Tailored treatment pathways for individual patients.
• Predictive Analytics: Early detection of disease progression.
• Simulation: Virtual testing of surgical or therapeutic interventions.
• Efficiency: Reduces trial‑and‑error in treatment planning.

Challenges in India

• Data Privacy: Sensitive patient data must comply with HIPAA/GDPR standards.
• Infrastructure Gaps: Many hospitals lack advanced imaging and AI integration.
• Cost Barriers: High investment in AI infrastructure and clinician training.
• Regulatory Pathways: Need for clear clinical validation and approvals.

India vs. Global Adoption

Aspect	India (Emerging)	Global (Advanced)
Infrastructure	Developing AI & imaging	Mature AI ecosystems
Clinical Trials	Limited, early stage	Extensive, multi‑center
Cost Accessibility	High barrier for hospitals	Wider adoption in developed nations
Focus Areas	Respiratory, oncology, preventive care	Cardiology, neurology, full‑body twins
Policy Support	National Digital Health Mission	Stronger regulatory frameworks

Outlook

India’s healthcare sector is embracing digital twin technology as part of its broader digital health transformation. With LTTS’s AI Lung Digital Twin, Apollo’s cardiac initiatives, IISc’s biomechanical research, and startup‑driven oncology solutions, the country is positioning itself as a future hub for AI‑driven diagnostics.

Scaling adoption will require investment in infrastructure, clinician training, and regulatory clarity, but the potential to revolutionize personalized medicine and predictive healthcare is undeniable.

India’s Pharma & MedTech Ecosystem Strengthened Through Infrastructure, Innovation, and Access Schemes

India’s pharmaceutical and medical technology sectors are undergoing a transformative phase, driven by a series of government-backed schemes that combine infrastructure development, innovation support, affordability initiatives, and regulatory strengthening. Together, these measures are positioning India as a global hub for pharmaceuticals, medical devices, and biopharmaceuticals.

Bulk Drug and Medical Device Parks

The Scheme for Promotion of Bulk Drug Parks is enabling the creation of common infrastructure for bulk drug manufacturing. Three parks have been approved in Andhra Pradesh, Gujarat, and Himachal Pradesh, with a combined project cost exceeding ₹6,306 crore. Each park is receiving ₹1,000 crore in central assistance.

The Scheme for Promotion of Medical Devices Parks supports advanced testing and laboratory facilities. Parks in Greater Noida (Uttar Pradesh), Ujjain (Madhya Pradesh), and Kanchipuram (Tamil Nadu) are at advanced stages of development, with a total project cost of ₹871 crore.

• 199 medical device manufacturers allotted land
• 306.64 acres distributed across three parks
• 34 units have commenced construction

Research, Innovation, and Affordable Access

The Promotion of Research and Innovation in Pharma MedTech (PRIP) scheme is fostering innovation-driven growth.

• 7 Centres of Excellence established at NIPERs
• 111 research projects approved
• 46 papers published
• 6 patents filed

The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has expanded access to low-cost medicines.

• 18,646 Jan Aushadhi Kendras operational
• 2,110 medicines and 315 medical devices available
• Over 100 crore sanitary pads sold at ₹1 each
• ₹8,000 crore savings for citizens in FY 2024-25
• ₹5,637 crore savings up to November 2025

Biopharma SHAKTI Initiative

Announced in the Union Budget 2026-27, Biopharma SHAKTI will invest ₹10,000 crore over five years to establish India as a global biopharmaceutical hub.

• Creation of biopharma-focused institutional network
• 3 new and 7 upgraded NIPERs
• 1,000 accredited clinical trial sites planned

Regulatory and Pricing Framework

India’s pharmaceutical governance is anchored by a strong regulatory ecosystem:

• CDSCO oversees drug approvals, clinical trials, and pharmacovigilance
• NPPA regulates drug prices under DPCO 2013
• IPC publishes the Indian Pharmacopoeia, recognized in 19 countries

Conclusion

India’s pharmaceutical ecosystem is evolving into a globally integrated, policy-supported system that balances scale, affordability, and regulatory credibility. Upcoming trade agreements with the European Union, United Kingdom, and New Zealand are expected to further enhance India’s pharmaceutical and medical devices sector.

New Terumo–Tata Elxsi Center to Accelerate AI-powered Medical Device Innovation

Tata Elxsi, a global leader in design and technology services, and Terumo Corporation, a leading Japan-based medical innovation company, have inaugurated the Terumo–Tata Elxsi Offshore Development Center. The new facility is dedicated to advancing cardiac and vascular solutions, strengthening engineering and innovation capabilities, and providing continuous lifecycle support across international markets.

Driving Next-Gen Medical Technologies

The center brings together multidisciplinary teams, combining Tata Elxsi’s expertise in design, engineering, verification, regulatory compliance, and localisation with cutting-edge applications of AI, GenAI, and digital technologies in software engineering. This integrated approach enables faster product development, regional adaptation, and improved cost efficiency while addressing the growing demand for patient-centric medical devices.

Enhancing Global Availability

By leveraging Tata Elxsi’s cross-functional capabilities, the collaboration aims to improve the reliability and performance of cardiovascular technologies, ensuring they meet stringent industry standards and the evolving needs of healthcare providers and patients worldwide.

Fumihisa Hirose, President of Terumo’s Cardiac & Vascular Company, emphasized the strategic importance of the center: “This new Offshore Development Center strengthens our ability to innovate faster and deliver high-quality medical technologies across global markets. Tata Elxsi’s integrated design, engineering, and regulatory expertise will help us accelerate our global product roadmap while maintaining the highest standards of safety and compliance.”

Sreevatsa Sahasranaman, Senior Vice President & Head – Healthcare & Life Sciences at Tata Elxsi, highlighted the long-term vision: "This Offshore Development Center represents a comprehensive partnership model with Terumo to bring Tata Elxsi’s multi-disciplinary expertise to drive innovation and cost efficiencies across Terumo’s cardiovascular portfolio. Enhanced by AI and GenAI-powered technologies, we are committed to helping Terumo deliver next-gen medical technologies to global and emerging markets.”

Strategic Impact

The collaboration marks a significant milestone in the healthcare technology sector, reinforcing India’s role as a hub for advanced engineering and design services while supporting Terumo’s mission to deliver innovative cardiovascular solutions worldwide.

4baseCare Partners with Bio Valley to Build India’s Next-Gen Genomics Hub in Vizag

In a significant step towards building India's Next-Generation Genomics ecosystem, Bio Valley, 4baseCare and Define Bio (P) Ltd. (Biobank) have signed a Memorandum of Understanding (MoU) to establish a Center of Excellence (CoE) named BioSphere dedicated to Genomics and Next-Generation Sequencing (NGS) at Andhra Pradesh MedTech Zone (AMTZ), Vizag.

The CoE-BioSphere shall strengthen national genomic infrastructure by enabling early and accurate diagnostics, informed therapeutic decisions, and advanced personalized treatments. By generating large-scale datasets reflecting India’s genetic diversity, along with the integration of relevant global genomic datasets, the CoE–BioSphere will support the development of Diagnostics, Risk prediction models, and therapies aligned with Indian genomic variations while maintaining international scientific benchmarks and interoperability. It also fosters structured research collaborations among Clinicians, Academic Institutions, Industry partners, and data-based Start-ups while also serving as a platform to train the Next Generation of Scientists and Entrepreneurs in data-driven research and product development

At a national level, population-scale genomic insights will contribute to evidence-based public health policy and preventive strategies, enhancing accessibility, affordability, and the long-term impact on healthcare in India.

“This collaboration with Bio Valley, 4baseCare and Define Bio represents a significant step in strengthening India’s innovation-led Biotech ecosystem at AMTZ. By bringing together advanced genomics expertise, incubation support, and translational research capabilities, we aim to accelerate the development of impactful precision medicine solutions. Partnerships like these reinforce our commitment to nurturing cutting-edge healthcare innovation from Andhra Pradesh and enabling globally relevant breakthroughs from India." - said Hitesh Goswami, CEO & Co-founder of 4baseCare

The key highlight of the initiative is the creation of a dedicated incubation center within CoE–BioSphere to nurture genomics-based startups. The center shall support emerging companies with sequencing services, access to data, and mentorship for product development. The CoE–BioSphere shall be a burgeoning hub for Genomics-driven Healthcare and Biotechnology advancements at AMTZ

“Building India's Next-Generation Genomic Ecosystem: This strategic partnership advances data-driven precision Healthcare solutions and Genomic innovation, marking a major achievement for personalized Medical solutions in India.” said - Dr. K. Suseela Branham, CEO Bio Valley.

Google DeepMind Unveils AlphaGenome: AI Tool to Decode DNA Mutations and Advance Precision Medicine

Google DeepMind has unveiled AlphaGenome, a breakthrough AI tool designed to predict the molecular impact of DNA mutations and accelerate biological discoveries. Published in Nature on January 28, 2026, AlphaGenome uses deep learning to analyze complex genetic sequences, helping scientists identify disease-causing mutations and understand how genetic changes influence health.

What AlphaGenome Does

• Interpret DNA mutations by analyzing millions of genetic letters and predicting their molecular consequences.
• Identify disease-causing genes, including those linked to cancer, heart disease, autoimmune disorders, and mental health conditions.
• Accelerate drug discovery by highlighting potential therapeutic targets.
• Enable faster biological research by reducing the time needed to analyze genetic data compared to traditional methods.

Why It Matters

• Healthcare Impact: AlphaGenome could transform precision medicine by helping clinicians understand which mutations are benign and which are pathogenic.
• Drug Development: By predicting how mutations affect proteins and cellular processes, it provides insights for pharmaceutical companies to design targeted therapies.
• Scientific Discovery: It offers researchers a powerful tool to decode the genome and uncover new biological mechanisms.

Comparison with Other AI in Genomics

Tool	Developer	Focus	Key Advantage
AlphaFold	DeepMind	Protein structure prediction	Revolutionized structural biology
AlphaGenome	DeepMind	DNA mutation impact	Predicts functional consequences of genetic variants
Enformer	Google Research	Gene expression prediction	Specialized in regulatory DNA regions
EVE (Evolutionary Model)	Harvard/Google	Variant pathogenicity	Uses evolutionary data for predictions

Risks & Challenges

• Clinical Validation: Predictions must be rigorously tested before being applied in patient care.
• Data Bias: AI models depend on training data; incomplete or biased datasets could affect accuracy.
• Ethical Concerns: Widespread use raises questions about genetic privacy and responsible application in healthcare.

Looking Ahead

AlphaGenome is available via API, allowing researchers worldwide to integrate it into their workflows. Its release signals a new era where AI becomes central to genomics and precision medicine, potentially reshaping how we diagnose, treat, and prevent genetic diseases.

Healthcare Self‑Reliance: India Now Manufactures 54 Life‑Saving Medical Devices

India’s MedTech manufacturing ecosystem has expanded to produce 54 unique medical technology products, ranging from advanced cancer-treatment equipment like Linear Accelerators (LINAC) to life-saving cardiac stents, under the government’s Production Linked Incentive (PLI) scheme.

Under the PLI Scheme for medical devices, 21 projects have started manufacturing of 54 unique medical devices, which include high end devices such as Linear Accelerator (LINAC), MRI, CT-Scan, Heart Valve, Stent, Dialyzer Machine, C-Arm, Cath Lab, Mammograph, MRI Coils, etc.

India’s MedTech Leap

• Scope of Products: India now manufactures 54 distinct MedTech devices, covering oncology (LINAC machines), cardiology (stents), imaging, diagnostics, and surgical equipment.
• Strategic Goal: Diversifies production, reduces import dependence, and strengthens domestic healthcare infrastructure.
• Policy Driver: The Production Linked Incentive (PLI) scheme has been central to this achievement.

📊 Why This Matters

• Healthcare Access: Domestic production lowers costs and improves availability for hospitals and patients.
• Economic Impact: MedTech contributes to India’s manufacturing revival, with ₹2 lakh crore in investments realized across PLI sectors by September 2025.
• Global Competitiveness: India is emerging as a hub for affordable MedTech exports.

Challenges & Trade-offs

• Quality Standards: Competing globally requires strict adherence to FDA and CE certifications.
• Supply Chain: Raw materials and specialized components may still rely on global suppliers.
• Innovation Gap: Sustained R&D investment is needed to match Western innovation.

Strategic Outlook

• Domestic Impact: Hospitals across India gain access to advanced devices like LINAC machines for cancer therapy.
• Export Potential: Affordable stents and diagnostic devices can boost India’s role in global healthcare supply chains.
• Policy Continuity: Continued government support through PLI and regulatory reforms will be critical.

In short:

India’s ability to manufacture 54 unique MedTech products—from LINACs to stents—signals a major step toward healthcare self-reliance and global competitiveness.

Piyush Goyal Strengthens Global Ties in Semiconductors, Carbon Capture and MedTech

Union Minister of Commerce and Industry Piyush Goyal has held a series of high-level meetings with global industry leaders to deepen collaborations in semiconductors, carbon capture, and medtech—three sectors critical to India’s long-term economic and technological ambitions.

Key meetings and partners

• Linde plc: CEO Sanjiv Lamba met with Goyal to discuss opportunities in advanced manufacturing, decarbonisation, and carbon capture technologies.
• Linde’s strategic role: A global leader in industrial gases and clean energy solutions, positioned as a key partner to strengthen India’s industrial ecosystem while aligning with sustainability goals.
• Intuitive Surgical: Senior executives engaged with Goyal on expanding robotic-assisted surgery in India; globally led by CEO Gary Guthart.
• Medtech impact: Collaboration could accelerate India’s adoption of cutting-edge medical robotics and modernize healthcare delivery.

Strategic importance

• Semiconductors & self-reliance: Build a major hub for chip production, reduce import reliance, and strengthen supply chain resilience.
• Carbon capture & clean tech: Partnerships with Linde support climate commitments and industrial decarbonisation.
• Healthcare modernization: Robotic surgery systems can improve patient outcomes and expand access to advanced procedures.

Challenges ahead

• Semiconductor supply chains: Fabs require massive capital, skilled talent, and geopolitical stability.
• Carbon capture costs: Technologies remain expensive and energy-intensive; scalability is a key hurdle.
• Medtech adoption: Robotic systems are costly, needing infrastructure upgrades and specialized training.

India’s Vision 2047

These engagements underscore India’s broader goal of becoming a self-reliant developed nation by 2047. By strengthening ties in semiconductors, clean tech, and medtech, India is positioning itself as a global innovation hub while advancing sustainability and healthcare.

MAHE & DST Launch India’s First Self-Financed MIDAS HUB for Medical Innovation

Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in collaboration with the Department of Science and Technology (DST), Government of India, launched the Medical Instruments, Devices and Allied Services (MIDAS) DST–MAHE HUB on Wednesday 5, 2025 at Manipal Campus, Karnataka. This is the first facility of its kind in a self-financed university.

Inaugurating the DST-MAHE HUB in the MAHE Manipal campus, Dr. Praveen Roy, Head of Scientific Divisions Technology, Translation, and Innovation (TTI) Division, Department of Science & Technology, Government of India, highlighted the critical importance of Translational innovation, which plays a critical role in strengthening India’s scientific ecosystem. He said, “We remain committed to supporting all activities of the MIDAS HUB. The DST–MAHE HUB is uniquely positioned, as MAHE’s multidisciplinary foundation enables seamless integration across diverse domains. This initiative represents a paradigm shift in our approach to research and innovation, and the Government of India will extend its full support to ensure its success.”

He also commended MAHE for its strong research ecosystem, which continues to advance impactful scientific progress for the society.

MIDAS DST–MAHE HUB Unveiled in MAHE Manipal

Dr. Praveen Roy, Scientist G, Department of Science & Technology, along with the Pro Chancellor and the Vice Chancellor of MAHE, releasing the MIDAS Annual Report during the inaugural event.

Addressing the occasion, Dr. H. S. Ballal, Pro Chancellor, MAHE, highlighted MAHE’s pivotal role in advancing collaborative, coordinated research and innovation. He emphasized, “the institution’s commitment to strengthening partnerships across academia, industry, and government, positioning MIDAS DST-MAHE HUB as a driving force for impactful scientific progress and societal benefit.”

Speaking at the event Lt. Gen. (Dr.) M. D. Venkatesh, VSM (Retd), Vice Chancellor, MAHE, expressively spoke about “the HUB’s pivotal role in nurturing high-impact research collaborations and cultivating future scientific leaders. He also appreciated the efforts put in by the team in establishing an excellent centre in the form of MIDAS HUB.”

The ceremony brought together distinguished leaders from academia, industry, and government. Delivering the welcome address Dr. G. Arun Maiya, Principal Coordinator of MIDAS HUB, presented an overview of HUB’s progress in medical device product development. Dr. Lazar Mathew, Senior Advisor, MIDAS HUB, unveiled the HUB logo and explained its philosophy, built around the theme “a project for a product.” The event was supported by MAHE’s key innovation and research entities, including the Directorate of Research, Manipal Universal Technology Business Incubator, Manipal GOK Bioincubator, Innovation Centre, and CAIF.

During the event, MAHE launched the Advanced Certificate Program in Medical Device Technology, Innovation and Leadership and released the MIDAS annual report. The HUB also introduced its industry–academia policy, service flyers, and signed multiple MoUs to foster long-term partnerships. Market-ready prototypes, including Laser Shoe, Mbilimeter, Armable Mini, WeCare, FluroAura, RevoCord, Wearable Electrolarynx, and Adrenaline Autoinjector—were showcased, reinforcing the HUB’s focus on impactful, deployable innovations.

The inauguration highlighted MAHE’s commitment to accelerating innovation in medical technology, strengthening industry–academia collaborations, and supporting translational research. MIDAS HUB aims to serve the entire West Coast innovation corridor, from Goa to Trivandrum, through partnerships with IIT Dharwad, IIT Palakkad, NITK Surathkal, Kannur University, Mahatma Gandhi University, BITS Goa, and leading industry players, including BPL, Philips, InBody, and Sparsh Technologies.